# Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors

> **NCT00420485** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 120 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** gimatecan

## Key facts

- **NCT ID:** NCT00420485
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2013-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420485, "Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00420485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*